Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 3, 2006, Pages 364-368

  Guven, Gulay Sain ^a   Kiliçaslan, Alpaslan ^a   Oz, S Gul ^a   Haznedaroglu, Ibrahim C ^a   Kirazli, Serafettin ^a   Aslan, Dilek ^a   Sözen, Tümay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Obesity; TAFI; Thrombosis

Indexed keywords

PROTHROMBIN; TETRAHYDROLIPSTATIN; THROMBIN INHIBITOR;

ADULT; ARTICLE; BLEEDING DISORDER; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; OBESITY; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOSIS; WEIGHT REDUCTION;

ADULT; BODY WEIGHTS AND MEASURES; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; HEMOSTASIS; HUMANS; LACTONES; MIDDLE AGED; OBESITY; THROMBOSIS;

EID: 33748741980     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606291403     Document Type: Article

References (33)

1. Fareed J, Hoppensteadt DA, Jeske WP, et al. Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost 1999;25:367.
2. Rosito GA, D'Agostino RB, Massaro J, et al. Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb Haemost 2004;91:683.
3. Eichinger S, Schonauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103:3773.
4. Guimaraes AH, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thromb Haemost 2004;91:473.
5. Bowles LK, Cooper JA, Howarth DJ, et al. Associations of haemostatic variables with body mass index: A community-based study. Blood Coagul Fibrinolysis 2003;14:569.
6. Bajzar L, Jain N, Wang P, Walker JB. Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis. Crit Care Med 2004;32:S320.
7. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb Haemost 2004;91:480.
8. Bouma BN, Meijers JC. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Semin Hematol 2004;41:13.
9. Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001;25:212.
10. Sudi KM, Gallistl S, Trobinger M, et al. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents. J Pediatr Endocrinol Metab. 2001;14:85.
11. Juhan-Vague I, Morange P, Christine AM. Fibrinolytic function and coronary risk. Curr Cardiol Rep 1999;1:119.
12. Mavri A, Stegnar M, Krebs M, et al. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999;19:1582.
13. Bruni F, Pasqui AL, Pastorelli M, et al. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects. Int J Cardiol 2004;95:269.
14. Guimaraes AH, van Tilburg NH, Vos HL, et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: Comparison of different assays. Br J Haematol 2004;124:659.
15. Schneider M, Brufatto N, Neill E, Nesheim M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004;279:13340.
16. Watanabe T, Minakami H, Sakata Y, et al. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol Obstet Invest 2004;58:19.
17. Zirlik A. TAFI: A promising drug target? Thromb Haemost 2004;91:420.
18. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002;25:899.
19. Turkoglu C, Duman BS, Gunay D, et al. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: Evidence supporting obesity as the central feature. Obes Surg 2003;13:699.
20. Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1. Metabolism 2002;51:471.
21. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:660.
22. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: Implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002;32:269.
23. Kohler HP. Insulin resistance syndrome: Interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002;132:241.
24. Lijnen HR, Maquoi E, Demeulemeester D, et al. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost 2002;88:345.
25. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002;3:85.
26. Cohn G, Valdes G, Capuzzi DM. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep 2001;3:416.
27. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001;60:341.
28. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000;32(Suppl 1):78.
29. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000;283:221.
30. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome - the optimal diet. Br J Nutr 2000;83(Suppl 1):S143.
31. de Leiva A. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes. 1998;106(Suppl 2): 10.
32. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998;52:329.
33. Juhan-Vague I, Vague P. Hypofibrinolysis and insulin-resistance. Diabete Metab 1991;17:96.